Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein–Barr virus DNA level and tumor response to palliative chemotherapy

Xue-Song Sun 1,2†, Li-Ting Liu 1,2†, Sai-Lan Liu 1,2†, Shan-Shan Guo 1,2, Yue-Feng Wen 1,2, Hao-Jun Xie 1,2, Qing-Nan Tang 1,2, Yu-Jing Liang 1,2, Xiao-Yun Li 1,2, Jin-Jie Yan 1,2, Jun Ma 1,3, Qiu-Yan Chen 1,2, Lin-Quan Tang 1,2* and Hai-Qiang Mai 1,2*

Abstract

Background: To evaluate the clinical outcome in patients with de novo metastatic nasopharyngeal carcinoma (NPC) treated or not treated with locoregional radiotherapy (LRRT) based on plasma Epstein–Barr virus (EBV) DNA level and tumor response after palliative chemotherapy (PCT).

Methods: From 2007 to 2016, 502 patients with de novo metastatic NPC were included in this study. All patients were treated with PCT and 315 patients received LRRT. Our primary study endpoint was overall survival (OS).

Results: EBV DNA was detected in 461 patients (91.8%) before treatment but was undetectable in 249 patients (49.6%) after PCT. Three hundred and seventeen patients (63.1%) achieved satisfactory response (complete response or partial response) to PCT. Both the post-PCT EBV DNA level and tumor response were independent prognostic factors. Among low-risk patients (patients with undetectable EBV DNA and satisfactory tumor response after PCT), the 3-year OS rate was 80.4% in LRRT-treated patients and 45.3% in patients not treated with LRRT (P < 0.001). Multivariate analyses demonstrated that LRRT was an independent prognostic factor of OS in the low-risk patients (P < 0.001). However, among the high-risk patients (patients with detectable EBV DNA and/or unsatisfactory response after PCT), no statistically significant survival differences were observed between the LRRT and non-LRRT groups.

(Continued on next page)
Background

Nasopharyngeal carcinoma (NPC) is a malignancy endemic in Southern China, where about 50–80 cases per 100,000 populations are reported each year [1]. According to its geographic distribution and biological characteristics, NPC is distinct from other head and neck cancers [2, 3]. Concurrent chemoradiation therapy (CCRT) is the standard treatment method among local advanced NPC patients [4, 5]. However, there are 6–15% of patients developing distant metastatic lesions before receiving any treatment. Bone, the lung, and the liver are the common metastatic sites [6, 7]. Treatment mostly relies on palliative chemotherapy (PCT) in these patients, with a median overall survival (OS) duration of 12–15 months [8, 9]. However, it was reported that survival rates could exceed 4 years for selected patients with metastatic NPC [10, 11]. Therefore, there is a need to identify the suitable factors for classifying high- or low-risk patients with metastatic NPC. According to National Comprehensive Cancer Network (NCCN) guidelines, chemotherapy combined with locoregional radiotherapy (LRRT) benefits selected patients with distant metastases at limited sites or with low tumor burden [12]. However, which type of patient should receive LRRT remains unclear. If the patients who would benefit from LRRT can be identified, a more intensive treatment strategy could be used to achieve a better clinical outcome.

Several studies have verified that plasma EBV DNA levels measured by real-time quantitative PCR are associated with NPC and can be used as a detection, monitoring, and prognostic prediction marker of non-metastatic NPC [13–17]. Besides, gross tumor volume showed a decreasing trend during treatment. In other types of cancer, tumor response to initial chemotherapy is related to outcome [18–21]. We have also verified the prognostic value of tumor response to neoadjuvant chemotherapy (NACT) among patients with locoregionally advanced NPC [22]. Hence, plasma EBV DNA level and tumor response to chemotherapy might aid the identification of patients who would benefit from LRRT. However, studies regarding plasma EBV DNA level and tumor response in metastatic NPC, especially de novo metastatic NPC are rare. Therefore, we initiated the present study to investigate the prognostic value of these two factors in patients with de novo metastatic NPC and to determine whether radiotherapy benefits these patients based on these two factors.

Methods

Patients

Between 2007 and 2016, 502 previously untreated patients with de novo metastatic NPC at our institute were included in the study. The eligibility criteria were: (1) biopsy-proven NPC; (2) received platinum-based PCT; (3) radiologically measurable disease; (4) Karnofsky performance score (KPS) > 60; (5) no secondary pregnancy, lactation, and other malignant disease; (6) normal renal and liver function; (7) available hematological sample results. Routine evaluations were applied on each patient: physical examination, head and neck magnetic resonance imaging (MRI) with contrast, chest radiography/ chest computed tomography (CT), abdominal sonography/ abdominal CT, nasopharyngoscopy and biopsy, bone scan and complete blood count that included differential cell counts, biochemical profile and EBV serology. Positron emission tomography/computed tomography (PET-CT) was also recommended if clinically indicated. The study is approved by Research Ethics Committee of our center.

Chemotherapy and radiotherapy

All eligible patients underwent one of the following chemotherapy regimens: PF (20–30 mg/m² cisplatin intravenously [IV] on days 1–3 plus 800–1000 mg/m² 5-fluorouracil continuous IV infusion for 24 h on days 1–5), GP (20–30 mg/m² cisplatin IV on days 1–3 plus 800–1000 mg/m² gemcitabine IV on days 1 and 8), TP (75 mg/m² docetaxel IV on day 1 plus 20–25 mg/m² cisplatin IV on days 1–3), TPF (60 mg/m² docetaxel IV on day 1 plus 20–25 mg/m² cisplatin IV on days 1–3 plus 500–800 mg/m² 5-fluorouracil continuous IV infusion for 24 h on days 1–5), or other. All regimens were administered every 3 weeks. The median cycle of PCT was five. After PCT, 315 patients were followed by LRRT. Among them, 72 patients received two-dimensional conventional radiotherapy (2D-CRT) and 243 patients received intensity-modulated radiotherapy (IMRT). The median radiation dose to the primary tumor was 70 Gy. The neck tissues received radiotherapy with a median dose of 66 Gy and 54 Gy in metastatic lymph node-positive and lymph node-negative region respectively. All patients were given 5 daily...
fractions per week and per fraction dose was range from 1.8 to 2.3 Gy. During radiotherapy, 168 patients received cisplatin (60–80 mg/m2)-based concurrent chemotherapy, which was administered every 3 weeks for two radiotherapy cycles [4, 23]. The IMRT plan was designed based on previous studies [24–26].

**Quantification of plasma EBV DNA levels and tumor response assessment**

Plasma EBV DNA levels were measured before treatment and after the completion of PCT. Plasma EBV DNA was extracted and subjected to real-time quantitative PCR. We established the post-chemotherapy cut-off value (0 copies/mL) previously [22]. To evaluate the tumor response to therapy, all patients underwent CT, MRI scan or bone scan (for bone metastases) and were classified as having complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) based on the Response Evaluation Criteria in Solid Tumors criteria [27]. Patients achieving CR or PR were considered as the satisfactory responders.

**Outcome and follow-up**

The primary endpoint of this study was overall survival (OS), which was defined as the time from the date of treatment to the date of death of any cause. After treatment completion, patients were inspected every 3 months in the first 3 years and every 6 months thereafter until death. MRI with contrast of head and neck, CT with contrast of the metastatic sites, Nasopharyngoscopy, chest radiography, abdominal sonography, bone scan, and plasma EBV DNA measurement were routinely performed or upon clinical indication of tumor relapse. PET-CT was considered if necessary.

**Statistical analyses**

The statistical analysis was performed using SPSS for Mac version 21.0 (SPSS Inc., Chicago, IL). The relationship between EBV DNA level or tumor response after PCT and the clinical patient characteristics of NPC were evaluated using the \( \chi^2 \) test and Fisher’s exact test. Kaplan–Meier survival curves were used to estimate the OS curves; survival rates were compared using the log-rank test. Step-wise multivariate analyses using Cox proportional hazard model were performed with the following variables: post-PCT EBV DNA level, tumor response to PCT, sex, age, T stage, N stage, metastatic site, chemotherapy regimen and LRRT. All analyses were 2-side. The level of significance was set at \( P < 0.05 \).

**Results**

**Clinical characteristics and overall survival**

Flow chart of patient inclusion was shown in Fig. 1. The median patient age was 47 years (range, 12–74 years); 417 patients (83.1%) were men; 315 patients (62.7%) received LRRT after PCT. In the cohort, 374 patients (74.5%) had one metastatic site, 226 patients (45.0%) had bone-only metastases, 64 patients (12.7%) had lung-only metastases, 49 patients (9.8%) had liver-only metastases, and 35 patients (7.0%) had distant nodal metastases. One hundred and twenty-eight patients (25.5%) had more than one metastatic site. Table 1 lists the characteristics of the 502 patients.

The median follow-up time was 26.3 months (range, 2–126 months). 272 patients died during follow-up. Among them, 269 patients died of tumor progression, 2 patients died of treatment-related toxicities (1 patient because of infection caused by leucopenia and 1 patient because of hepatic failure) and 1 patient died of cardiac disease. EBV DNA levels could be detected in 461 patients before PCT. However, only 253 patients had detectable EBV DNA levels after PCT. Among the entire cohort, two patients had CR, 315 patients had PR, 114 patients had SD, and 71 patients had PD. As shown in Additional file 1: Table S1, the tumor responses were significantly different between patients with post-PCT undetectable plasma EBV DNA levels (CR/PR = 208 of 249 assessable patients) and patients with detectable levels (CR/PR = 109 of 253 assessable patients) (\( P < 0.001 \)).

**Relationship between EBV DNA level, tumor response, and clinical outcome**

The 3-year OS rate in patients with undetectable EBV DNA levels after PCT was significantly higher than that in the patients with detectable EBV DNA levels (69.2, 95% confidence interval [CI] 62.9–75.5% versus 33.8, 95% CI 27.1–40.5%, \( P < 0.001 \)) (Fig. 2a). Unsatisfactory tumor responses predicted worse 3-year OS rate compared with satisfactory responses (62.8, 95% CI 56.9–68.7% versus 33.6, 95% CI 26.0–41.2%, \( P < 0.001 \)) (Fig. 2b). We carried out multivariate analyses that included post-PCT EBV DNA level (undetectable or detectable), post-PCT tumor response (CR/PR or SD/PD), patient age (<47 years or ≥47), sex (male or female), T stage (\( T_{1–2} \) or \( T_{3–4} \) ), N stage (\( N_{0–1} \) or \( N_{2–3} \) ), chemotherapy regimen (TPF, TP, PF, GP, or other), metastatic site (bone, lung, liver, distant nodal or multiple metastatic sites), and whether PCT was followed by LRRT. Table 2 shows that a significant prognostic value was indicated for both the post-PCT EBV DNA level and tumor response in the multivariate model for OS (EBV DNA level: hazard ratio [HR] 2.13, 95% CI 1.58–2.88, \( P < 0.001 \); tumor response: HR 1.34, 95% CI 1.02–1.77, \( P = 0.036 \)).

**Risk stratification**

Post-PCT EBV DNA level and tumor response were significantly correlated with prognosis in de novo metastatic NPC. Moreover, the patients with undetectable
post-PCT EBV DNA and satisfactory tumor response (CR/PR) had significantly better clinical OS than the patients with either detectable post-PCT EBV DNA or unsatisfactory tumor response (SD/PD); the 3-year OS rates were 73.9 and 36.5% (P < 0.001) respectively (Fig. 2c). Accordingly, we divided the patients into low-risk (undetectable EBV DNA and satisfactory tumor response post-PCT) and high-risk groups (detectable EBV DNA and/or unsatisfactory tumor response post-PCT). Table 3 lists the patient characteristics according to risk group.

The relationship between post-PCT LRRT and outcome in patients according to risk group

In the low-risk group, the 3-year OS rate was 80.4% in LRRT-treated patients and 45.3% in patients not treated with LRRT (P < 0.001). However, in the high-risk group, the 3-year OS rate was similar in patients treated or not treated with LRRT (40.2% vs. 31.0%, P = 0.111). Figure 3a, b shows the Kaplan–Meier survival curves. Landmark analyses were performed for patients surviving ≥1 year. Similarly, the survival benefit of LRRT for the survivors was only found in low-risk group (Fig. 3c, d). We carried out two separate multivariate analyses of the low- and high-risk patients. Table 4 shows that in the low-risk group, a strong prognostic value was indicated for LRRT for OS (HR 0.35, 95% CI 0.21–0.58, P < 0.001). However, LRRT did not show significant survival benefits for the high-risk group.

Discussion

Distant metastasis has been a leading cause of death in patients with NPC, and there is no effective treatment for such patients [28, 29]. The management of metastatic NPC remains a crucial clinical challenge. The development of modern treatment modalities (e.g., IMRT, tomotherapy, targeted therapy, biotherapy) makes individualized treatment increasingly important, as these
treatments are expensive and toxic. PCT is usually recommended for improving long-term survival. However, the benefits of LRRT in different types of patients with de novo metastatic NPC have not been clearly evaluated. This lack of understanding has hindered individualized treatment of metastatic NPC. There is a need to integrate biomarkers and diagnostic imaging assays to determine the risk of poor outcome in individual patients and the type of patient who would benefit from subsequent radiotherapy. Thus, we divided patients with de novo metastatic NPC into high- and low-risk groups based on EBV DNA level and tumor response to PCT, and found that post-PCT LRRT could significantly reduce the risk of death in low-risk patients.

Many reports have proven the value of LRRT in patients with metastatic NPC. Among patients with distant metastases of NPC at diagnosis, Chen et al. proved that patients who received LRRT plus systemic chemotherapy

Table 1 Clinical characteristics of patients with de novo metastatic NPC (n = 502)

| Characteristic | EBV DNA levels after PCT | Tumor response to PCT |
|---------------|--------------------------|----------------------|
|               | Undetectable | Detectable | P-value | CR/PR | SD/PD | P-value |
| Total         | 249 | 253 | 317 | 185 |  |
| Gender        |        |        | 0.552 | 0.460 | 0.460 |
| Male          | 204 (81.9%) | 213 (84.2%) | 260 (82.0%) | 157 (84.9%) |
| Female        | 45 (18.1%) | 40 (15.8%) | 57 (18.0%) | 28 (15.1%) |
| Age (years)   |        |        | 0.533 | 1.000 |  |
| ≤ 47          | 133 (53.4%) | 128 (50.6%) | 165 (52.1%) | 96 (51.9%) |
| > 47          | 116 (46.6%) | 125 (49.4%) | 152 (47.9%) | 89 (48.1%) |
| T stage       |        |        | 1.000 | 0.467 |  |
| T1            | 10 (4.0%) | 11 (4.3%) | 10 (3.2%) | 11 (5.9%) |
| T2            | 31 (12.4%) | 32 (12.6%) | 39 (12.3%) | 24 (13.0%) |
| T3            | 123 (49.4%) | 125 (49.4%) | 161 (50.8%) | 87 (47.0%) |
| T4            | 85 (34.1%) | 85 (33.6%) | 107 (33.8%) | 63 (34.1%) |
| N stage       |        |        | 0.002 | 0.790 |  |
| N0            | 13 (5.2%) | 3 (1.2%) | 11 (3.5%) | 5 (2.7%) |
| N1            | 53 (21.3%) | 36 (14.2%) | 55 (17.4%) | 34 (18.4%) |
| N2            | 101 (40.6%) | 101 (39.9%) | 132 (41.6%) | 70 (37.8%) |
| N3            | 82 (32.9%) | 113 (44.7%) | 119 (37.5%) | 76 (41.1%) |
| Metastatic sites |        |        | < 0.001 | < 0.001 |  |
| Bone          | 130 (52.2%) | 96 (37.9%) | 157 (49.5%) | 69 (37.3%) |
| Lung          | 44 (17.7%) | 20 (7.9%) | 48 (15.1%) | 16 (8.6%) |
| Liver         | 20 (8.0%) | 29 (11.5%) | 28 (8.8%) | 21 (11.4%) |
| Distant nodal | 23 (9.2%) | 12 (4.7%) | 27 (8.5%) | 8 (4.3%) |
| Multiple sites | 32 (12.9%) | 96 (37.9%) | 57 (18.0%) | 71 (38.4%) |
| PCT regimens  |        |        | 0.081 | 0.639 |  |
| TPF           | 77 (30.9%) | 53 (20.9%) | 85 (26.8%) | 45 (24.3%) |
| TP            | 59 (23.7%) | 62 (24.5%) | 81 (25.6%) | 40 (21.6%) |
| PF            | 63 (25.3%) | 68 (26.9%) | 78 (24.6%) | 53 (28.6%) |
| GP            | 10 (4.0%) | 17 (6.7%) | 18 (5.7%) | 9 (4.9%) |
| Others        | 40 (16.1%) | 53 (20.9%) | 55 (17.4%) | 38 (20.5%) |
| LRRT          |        |        | < 0.001 | < 0.002 |  |
| Yes           | 194 (77.9%) | 121 (47.8%) | 219 (69.1%) | 96 (51.9%) |
| No            | 55 (22.1%) | 132 (52.2%) | 98 (30.9%) | 89 (48.1%) |

Abbreviations: EBV Epstein-Barr virus, PCT palliative chemotherapy, CR complete response, PR partial response, PD disease progression, SD stable disease, TPF cisplatin plus docetaxel plus 5-fluorouracil, TP cisplatin plus docetaxel, PF cisplatin plus 5-fluorouracil, GP cisplatin plus gemcitabine, LRRT locoregional radiotherapy

Undetectable/detectable EBV-DNA levels after PCT is based on a cutoff value of 0 copies per milliliter

P-value was calculated with the Pearson $\chi^2$ test
had higher survival rates compared with patients who received systemic chemotherapy alone [30]. According to Khot et al., patients with NPC with bone-only oligometastatic lesions could benefit from LRRT [31]. Moreover, the NCCN guidelines state that patients with metastatic NPC with limited sites or with low tumor burden would benefit from LRRT [12]. Under the background, Zou et al. divided patients with de novo metastatic NPC into three subgroups according survival outcome: M1a, no liver involvement and oligometastases; M1b, no liver involvement and multiple metastases; and M1c, liver involvement regardless of the number of distant metastases. They reported that LRRT combined with chemotherapy benefited patients identified as M1a/M1b but did not result in better clinical outcome for patients classified as M1c [32]. In our study, 315 patients were followed by LRRT after PCT and 187 patients received PCT only. The median cycle of PCT was five (three weeks a cycle). Between chemotherapy and RT initiation, the median of time intervals were 21 days (range: 10–38 days). There is potential for immortal time bias. Only patients that survive long enough can actually receive radiation and patients that die or progress before they can get LRRT cannot possibly receive LRRT. The observations of consistent benefits with RT on landmark analyses suggest that this form of bias could not affect our results.

Plasma EBV DNA level and tumor response correlate with the tumor burden and prognosis [13–15]. In the present study, patients with undetectable plasma EBV DNA levels after PCT had significantly better clinical outcome than patients with detectable EBV DNA levels. Similarly, satisfactory tumor response predicted better OS compared with unsatisfactory response. The results are accordance with our previous study of patients with locoregionally advanced NPC [22]. For patients with metastatic or recurrent NPC, An et al. have suggested that undetectable post-treatment plasma EBV DNA indicates better tumor response [33]. Moreover, it was inspiring to observe that patients in our study with both undetectable plasma EBV DNA and satisfactory tumor response post-PCT had a 3-year OS rate of 73.9%, which is significantly higher than that in patients with detectable EBV DNA and/or unsatisfactory tumor response post-PCT (36.5%). Accordingly, considering these two factors, we divided the patients into low-risk (undetectable EBV DNA and satisfactory tumor response post-PCT) and high-risk groups (detectable EBV DNA and/or unsatisfactory tumor response post-PCT). We explored the efficacy of additional post-PCT LRRT in the patients according to risk group. Interestingly, in the low-risk group, patients who received post-PCT LRRT had significantly better OS compared to the patients who did not. This might be because the low-risk patients were sensitive to PCT and that the distant lesions were under better control. Local control may be important to long-term survival in this kind of patients. Therefore, it is more important to control the locoregional disease by post-PCT LRRT. However, for high-risk patients, the distant lesions were not under control and the post-PCT LRRT might have been insufficient for controlling the

![Fig. 2](image-url)  
**Fig. 2** Kaplan–Meier OS curves in 502 patients with de novo metastatic NPC. (a) Patients grouped according to EBV DNA level after PCT. (b) Patients grouped according to tumor response after PCT. (c) Patients grouped according to risk stratification.

| Table 2 | Multivariate analysis using step-wise method |
|---------|---------------------------------------------|
| Characteristic | HR  | 95% CI | P-value |
| EBV DNA level | 2.13 | 1.58–2.88 | <0.001 |
| Tumor response | 1.34 | 1.02–1.77 | 0.036 |
| N stage | 1.40 | 1.02–1.91 | 0.036 |
| Metastatic site | | | |
| Lung vs. Bone | 0.89 | 0.58–1.36 | 0.589 |
| Liver vs. Bone | 1.00 | 0.66–1.51 | 0.993 |
| Distant nodal vs. Bone | 0.98 | 0.52–1.84 | 0.956 |
| Multiple vs. Bone | 2.39 | 1.77–3.23 | <0.001 |
| LRRT | 0.76 | 0.59–0.98 | 0.037 |

All factors were involved in the analysis and five factors remained. 
Abbreviations: EBV Epstein-Barr virus, HR hazard ratio, CI confidence interval, LRRT locoregional radiotherapy.
All potential prognostic factors were involved in the analysis and five factors remained. 
HRs were calculated for N stage (N2–3 vs. N0–1); LRRT (Yes vs. No); EBV DNA level (Detectable vs. Undetectable) and Tumor response (SD/PD vs. CR/PR).
distant lesions. Intensive treatment such as the administration of target agent or the addition of immunotherapy might be necessary for such patients to control the distant lesions [34, 35]. Therefore, we did not observe a significant survival benefit of post-PCT LRRT in these patients.

There are several limitations to this study. First, the study involved only 502 patients, and the number of patients between subgroups differed which is an unavoidable bias because of the small sample size. Second, the data were from one center; the results should be validated by a multi-centric clinical study. The third limitation is that the median follow-up duration was 26.3 months. A longer follow-up period is necessary to evaluate the long-term outcomes of these patients and to validate our results.

### Conclusion

In conclusion, EBV DNA level and tumor response after PCT are closely related with the clinical outcome of de novo metastatic NPC. Patients with undetectable EBV DNA and satisfactory tumor response after PCT could benefit from the addition post-PCT LRRT. This finding would identify patients at different risk of treatment failure and guide individualized therapy. Further investigation is necessary to confirm our findings.

#### Table 3 Clinical characteristics of patients with de novo metastatic NPC according to risk after PCT

| Characteristic       | Low-risk patients (n = 208) | High-risk patients (n = 294) |
|----------------------|-----------------------------|-----------------------------|
|                      | LRRT | Non-LRRT | P-value | LRRT | Non-LRRT | P-value |
| Total                | 165  | 43       |         | 150  | 144      |         |
| Gender               |      |          |         |      |          |         |
| Male                 | 134  | (81.2%)  | 0.828   | 128  | (85.3%)  | 0.871   |
| Female               | 31   | (18.8%)  | 0.828   | 22   | (14.7%)  | 0.871   |
| Age (years)          |      |          |         |      |          |         |
| ≤ 47                 | 94   | (57.0%)  | 0.169   | 77   | (51.3%)  | 0.816   |
| > 47                 | 71   | (43.0%)  | 0.169   | 73   | (48.7%)  | 0.816   |
| T stage              |      |          |         |      |          |         |
| T1                   | 5    | (3.0%)   | 0.495*  | 6    | (4.0%)   | 0.458   |
| T2                   | 22   | (13.3%)  | 0.495*  | 22   | (14.7%)  | 0.458   |
| T3                   | 83   | (50.3%)  | 0.495*  | 71   | (47.3%)  | 0.458   |
| T4                   | 55   | (33.3%)  | 0.495*  | 51   | (34.0%)  | 0.458   |
| N stage              |      |          |         |      |          |         |
| N0                   | 9    | (5.5%)   | 0.362   | 4    | (2.7%)   | 0.452*  |
| N1                   | 33   | (20.0%)  | 0.362   | 29   | (19.3%)  | 0.452*  |
| N2                   | 73   | (44.2%)  | 0.362   | 52   | (34.7%)  | 0.452*  |
| N3                   | 50   | (30.3%)  | 0.362   | 65   | (43.8%)  | 0.452*  |
| Metastatic sites     |      |          |         |      |          |         |
| Bone                 | 99   | (60.0%)  | < 0.001*| 64   | (42.7%)  | 0.006   |
| Lung                 | 25(15.2)| 13 | (30.2%) | 15 | (10.0%) | (7.6%)) |
| Liver                | 9    | (5.5%)   | 0.362   | 14   | (9.3%)   | 0.452*  |
| Distant nodal        | 20   | (12.1%)  | 0.362   | 13   | (8.7%)   | 0.452*  |
| Multiple sites       | 12   | (7.3%)   | 0.362   | 44   | (29.3%)  | 0.452*  |
| PCT regimens         |      |          |         |      |          |         |
| TPF                  | 55   | (33.3%)  | 0.021   | 33   | (22.0%)  | 0.180   |
| TP                   | 46   | (27.9%)  | 0.021   | 39   | (26.0%)  | 0.201   |
| PF                   | 33   | (20.0%)  | 0.021   | 40   | (26.7%)  | 0.201   |
| GP                   | 4    | (2.4%)   | 0.021   | 5    | (3.3%)   | 0.201   |
| Others               | 27   | (16.4%)  | 0.021   | 33   | (22.0%)  | 0.201   |

Abbreviations: LRRT locoregional radiotherapy, TPF cisplatin plus docetaxel plus 5-fluorouracil, TP cisplatin plus docetaxel, PF cisplatin plus 5-fluorouracil, GP cisplatin plus gemcitabine

P-value was calculated with the Pearson χ² test or Fisher’s exact test (*)
Fig. 3  Comparison of OS of patients in the LRRT and non-LRRT group: (a) Low-risk patients (patients with undetectable EBV DNA level and satisfactory tumor response post-PCT) (b) High-risk patients (patients with detectable EBV DNA level or/and unsatisfactory tumor response post-PCT) (c) Landmark analyses of overall survival for long-term survivors of ≥1 year in low risk group (d) Landmark analyses of overall survival for long-term survivors of ≥1 year in high risk group.

Table 4  Multivariate analysis of OS in low- and high-risk patients after PCT using step-wise method

| Characteristic   | Low-risk patients | High-risk patients |
|------------------|-------------------|--------------------|
|                  | HR    | 95% CI       | P-value | HR    | 95% CI       | P-value |
| Age (years)      | NS    |              |         | 1.27  | 0.96–1.68    | 0.089   |
| N stage          | 1.85  | 0.99–3.45    | 0.055   | 1.38  | 0.97–1.96    | 0.074   |
| Metastatic site  |       |              |         | 0.83  | 0.48–1.42    | 0.493   |
| Lung vs. Bone    | NS    |              |         | 1.03  | 0.65–1.62    | 0.911   |
| Liver vs. Bone   | NS    |              |         | 0.90  | 0.43–1.87    | 0.774   |
| Distant nodal vs. Bone | NS |              |         | 2.94  | 2.10–4.11    | < 0.001 |
| Multiple vs. Bone| NS    |              |         | 0.35  | 0.21–0.58    | < 0.001 |

Abbreviations: NS non-significant, HR hazard ratio, CI confidence interval, LRRT locoregional radiotherapy

All potential prognostic factors were involved in the analysis. Two factors remained in low-risk patients and three factors remained in high-risk patients. HRs were calculated for Age (years) (>47 vs. ≤47); N stage (N2–3 vs. N0–1); LRRT (Yes vs. No).
Additional file

Additional file 1: Table S1. Relationship between EBV DNA levels after PCT and tumor response to PCT. (DOXC 49 kb)

Abbreviations

2D-CRT: Two-dimensional conventional radiotherapy; CI: Confidence interval; CR: Complete response; CT: Computed tomography; EBV: Epstein–Barr virus; HR: Hazard ratio; IMRT: Intensity-modulated radiotherapy; KPS: Karnofsky performance score; LRRT: Locoregional radiotherapy; MR: Magnetic resonance imaging; NPC: Nasopharyngeal carcinoma; QOL: Overall survival; PCT: Palliative chemotherapy; PD: Progressive disease; PET-CT: Positron emission tomography/computed tomography; PR: Partial response; SD: Stable disease

Acknowledgments

We kindly thank the editor and reviewers for careful review and valuable comments, which have led to a significant improvement of the manuscript.

Funding

Study design: the National Key R&D Program of China (2016YFC0902003,2017YFC1309003,2017YFC0908500), the National Natural Science Foundation of China (No. 81425018, No. 81672868, No. 81602371), the Sun yat-sen University Clinical Research 510060, People’s Republic of China. 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, People’s Republic of China.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Study concepts: HQM, LQT. Study concepts: HQM, LQT. Study design: XSS, LTL, SLL. Data acquisition: XSS, LTL, SLL, YJL, XYL, JFY, SSG, YFW, HJX, QNT. Data analysis and interpretation: the cultivation foundation for the junior teachers in Sun Yat Sen University(16ykj28), the foundation for major project and new cross subject in Sun Yat Sen University(16ykj28) and the Fundamental Research Funds for the Central Universities Fundamental Research Funds for the Central Universities.

Ethics approval and consent to participate

This retrospective study was approved by the Clinical Research Committee of Sun Yat-sen University Cancer Center. Patients were required to provide written informed consent before enrolling in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a “Cantonese cancer”? Chin J Cancer. 2010;29(5):517–26.
2. Choa G. Nasopharyngeal carcinoma. Some observations on the clinical features and technique of examination. Pac Med Surg. 1967;75(3):172–4.
3. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–9.
4. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vudong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310–7.
5. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21(4):631–7.
6. Lee AW, Ng WT, Chan YH, She H, Chan C, Lam TH. The battle against nasopharyngeal cancer. Radiother Oncol. 2012;104(3):272–8.
7. Wei WL, Sham JS. Nasopharyngeal carcinoma. Lancet (London, England). 2005;365(9467):2041–54.
8. Loong HH, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am. 2008;22(6):1267–78 x.
9. Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008;99(7):1311–8.
10. Fandi A, Bachouchi M, Adhi N, Taamanna A, Bousseen H, Wilbault P, Eschege F, Amund JP, Simon J, Cividivi E. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol. 2000;18(2):1324–30.
11. Hui EP, Leung SF, Au JS, Zee B, Tsang S, Chua D, Sze WM, Law CK, Leung TW, Chan AT. Lymphoma metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong nasopharyngeal carcinoma study group. Cancer. 2004;101(2):300–6.
12. Pfister DG, Ang K, Briell OM, Bunttress BA, Busse PM, Caudell JJ, Cerelak AJ, Coley AS, Dunphy F, Eisele DW, et al. Head and neck cancers, version 2. 2013. Updated features to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917–23.
13. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59(6):1188–91.
14. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461–70.
15. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, Chan KC, Chan LY, Kwan WH, Lo YM, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24(34):5414–8.
16. Li YH, Shao JY, Zhao MQ, Gao HY, Li LR, Guan ZZ, Zeng YX. Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy. Ai Zheng. 2003;22(6):645–48.
17. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Fennberg L, Zeng YX. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin a/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004;100(2):1162–70.
18. Visser JH, Wessels G, Hesseling PB, Louw I, Oberholster E, Mansvelt EP. Prognostic value of day 14 blast percentage and the absolute blast index in
bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001;18(3):187–91.
19. Picci P, Rougaff BT, Bacci G, Neff JR, Sangjorgi L, Cazzola A, Baldini N, Ferrari S, Mercuri M, Ruggieri P, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993;11(9):1763–9.
20. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106(5):1154–61.
21. Rosen G, Caparros B, Groshen S, Nierenberg A, Cacavio A, Marcove RC, Lane JM, Huvos AG. Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors. Cancer Invest. 1984;2(3):181–92.
22. Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, Mo HY, Zhao C, Guo X, Cao K, et al. The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9.
23. Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjunct to induction-concurrent chemoradiotherapy, changing from fluorouracil to capetibine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121(8):1328–38.
24. Lee AW, Lau KY, Hung WM, Ng WT, Lee MC, Choi CW, Chan CC, Tung R, Cheng PT, Yau TK. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol. 2008;87(2):204–10.
25. Lin S, Lu JJ, Han L, Chen Q, Pan J. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer. 2010;10:39.
26. Yu Z, Luo W, Zhou QC, Zhang QH, Kang DH, Liu MZ. Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma. Ai Zheng. 2009;28(11):1132–7.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
28. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer. 1996;77(2):2423–31.
29. Sham JS, Choy D, Choi PH. Nasopharyngeal carcinoma: the significance of neck node involvement in relation to the pattern of distant failure. Br J Radiol. 1990;63(746):108–13.
30. Chen MY, Jiang R, Guo L, Zou X, Liu Q, Sun R, Qiu F, Xia ZJ, Huang HQ, Zhang L, et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer. 2013;32(11):604–13.
31. Khot A, Love C, Garg MK, Haigentz M Jr. Long-term disease control in a patient with recurrent bone-only Oligometastatic nasopharyngeal carcinoma. J Clin Oncol. 2016;34(4):e25–6.
32. Zou X, You R, Liu H, He YX, Xie GF, Xie ZH, Li JB, Jiang R, Liu LZ, Li L, et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer. 2017;77:117–26.
33. An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao YJ, Li YH. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117(16):5750–7.
34. Masmoudi A, Touni N, Kharif A, Kallel-Slimi L, Daoud J, Karray H, Frikha M. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. Cancer Treat Rev. 2007;33(6):499–505.
35. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46(1):1–10.